Abstract 54P
Background
Previous clinical research has demonstrated that immunotherapy plus anti-angiogenesis have a synergistic effect and achieved promising clinical outcomes in treating advanced NSCLC patients as first-line therapy. However, there are limited data for immunotherapy plus anti-angiogenesis as second-line or salvage therapy. Herein, we conduct a retrospective study to evaluate the efficacy of immunotherapy in combination with anti-angiogenesis as second-line or later therapy for patients with advanced NSCLC in the real world.
Methods
We retrospectively enrolled eligible patients with advanced NSCLC who were treated with immunotherapy plus anti-angiogenesis (I+A group) or immunotherapy monotherapy (IM group) as second-line or later therapy at Shanghai Chest Hospital from January 1, 2018, to March 30, 2022. The clinical information was collected, and the treatment outcomes and survival data were assessed and compared between the two groups.
Results
A total of 211 patients were included in this study (83 patients in the I+A group and 128 patients in the IM group). The I+A group achieved a higher objective response rate (ORR) compared with the IM group (27.7% VS. 3.9%, P < 0.001). The median progression-free survival (PFS) was 6.77 months VS. 4.67 months (P < 0.001), and the median overall survival (OS) was 16.73 months VS. 12.63 months (P = 0.035), respectively. In the subgroup analysis, patients who received immunotherapy as second-line treatment were more likely to benefit from combination therapy (mPFS: 8.93months VS. 4.03 months, P < 0.001). Additionally, multivariate analysis showed that immunotherapy plus anti-angiogenesis had significantly prolonged the PFS and OS (P = 0.011 and P = 0.008).
Conclusions
Immunotherapy plus anti-angiogenesis achieved longer PFS and OS in patients with advanced NSCLC in the second-line or posterior treatment. Further prospective research should be conducted on larger populations.
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (No. 82072573, 82002426)
Disclosure
All authors have declared no conflicts of interest.